Healthpeak Properties
DOC
$20.09
-1.66%
Healthpeak Properties, Inc. is a real estate investment trust (REIT) specializing in healthcare facilities, owning a diversified portfolio of approximately 700 properties primarily focused on medical office and life science assets, with additional holdings in senior housing, hospitals, and skilled nursing. The company is a prominent player in the healthcare real estate sector, leveraging its scale and specialized property focus to serve the essential and growing healthcare industry. The current investor narrative centers on the stock's significant price appreciation and momentum, driven by a recent surge in May 2026, amidst ongoing analysis of its portfolio's performance and the stability of its core medical office and life science segments.…
DOC
Healthpeak Properties
$20.09
Investment Opinion: Should I buy DOC Today?
Rating & Thesis: Hold. While the technical breakout is compelling, the extreme valuation and inconsistent fundamentals create an unfavorable risk/reward profile, making the stock unsuitable for new investment at current levels. The mixed analyst sentiment, with recent downgrades and no clear average target price, supports a neutral stance.
Supporting Evidence: The stock's trailing PE of 156.9x is astronomically high for a REIT, especially one with only 3.07% YoY revenue growth. Its Price-to-Sales ratio of 3.97 and EV/EBITDA of 13.16 are more standard for the sector but do not offset the earnings multiple concern. Profitability metrics are weak, with a TTM net margin of 2.53% and ROE of 0.95%. The sole fundamental bright spot is strong TTM FCF of $1.17B, but this is already reflected in the price following the 27.72% YTD surge.
Risks & Conditions: The two biggest risks are 1) a failure to grow earnings into its lofty valuation, triggering a multiple compression, and 2) a reversal of the powerful technical momentum. This Hold rating would upgrade to a Buy only if the stock experiences a significant pullback (e.g., below $17) to a more reasonable valuation, or if quarterly earnings demonstrate consistent, strong growth that justifies the premium. It would downgrade to a Sell if revenue growth stalls or turns negative, or if the technical breakdown below key support (e.g., $19) confirms the momentum has reversed. The stock is overvalued relative to its own history and its current growth profile.
Sign up to view all
DOC 12-Month Price Forecast
The investment thesis for DOC is a clash between compelling technical momentum and untenable fundamental valuation. The stock's surge has pushed it to a precarious position where any disappointment could trigger a sharp correction. The most likely path is consolidation and range-bound trading as the market digests the move and awaits clearer evidence of earnings growth. The stance is neutral due to this high risk/reward asymmetry. We would upgrade to bullish only on a meaningful pullback that resets valuation expectations, or on clear evidence of sustained, high-margin earnings growth. A downgrade to bearish would be triggered by a breakdown of the $19 support level or a quarterly earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $26.12 and implied upside of +30.0% versus the current price.
Average Target
$26.12
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$16 - $26
Analyst target range
Analyst coverage for DOC is limited, with only 5 analysts providing estimates according to the data. The consensus sentiment appears mixed, as institutional ratings show a recent pattern of downgrades to 'Hold' from firms like Argus Research and Jefferies in early 2026, alongside maintained 'Outperform' or 'Overweight' ratings from others like Evercore ISI and Morgan Stanley. An average target price is not explicitly provided in the data, indicating insufficient consensus to calculate a clear implied upside or downside from the current price of $20.69. The target range for estimated revenue is wide, spanning from a low of $3.22 billion to a high of $3.96 billion, with an average estimate of $3.67 billion. This wide dispersion signals high uncertainty among analysts regarding the company's future revenue trajectory. The pattern of recent rating changes, including two downgrades to Hold in February 2026, suggests some analysts are becoming more cautious despite the stock's strong price performance. Limited coverage can lead to higher volatility and less efficient price discovery for this mid-cap REIT.
Bulls vs Bears: DOC Investment Factors
The bull case is primarily driven by powerful technical momentum and the defensive, cash-generating nature of its healthcare real estate portfolio. The bear case centers on a valuation that appears disconnected from the company's inconsistent fundamentals and low profitability. Currently, the technical momentum is the dominant force, but the evidence from fundamentals and valuation strongly favors the bearish perspective. The single most important tension is between the stock's explosive price action and its extreme valuation multiples. If the company cannot deliver significantly accelerated earnings growth to justify its PE ratios, the current price level is unsustainable.
Bullish
- Powerful Technical Breakout: The stock has surged +21.85% over the past 3 months and +5.83% over the past month, significantly outperforming the S&P 500. It is trading at 99.4% of its 52-week high, indicating strong momentum and a confirmed bullish trend.
- Strong Free Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $1.17 billion. This provides financial flexibility for dividends, debt reduction, and strategic investments, underpinning the REIT's operational stability.
- Essential Healthcare Portfolio: Healthpeak owns a portfolio of approximately 700 essential healthcare properties, primarily in medical office and life science assets. This provides defensive, non-cyclical cash flow supported by the structural demand tailwinds of the healthcare sector.
- Improving Quarterly Revenue Trend: Revenue has grown sequentially from $694.3M in Q2 2025 to $719.4M in Q4 2025, with Q4 revenue up 3.07% YoY. This indicates a positive, albeit modest, fundamental growth trajectory.
Bearish
- Extremely High Valuation Multiples: The stock trades at a trailing PE of 156.9x and a forward PE of 137.9x, which is near the extreme high end of its historical range. This premium valuation is difficult to justify given its modest 3% revenue growth and inconsistent profitability.
- Inconsistent & Low Profitability: Profitability is highly volatile, with a Q3 2025 net loss of -$117.1M swinging to a Q4 profit of $114.0M. The TTM net margin is a thin 2.53%, and ROE is a low 0.95%, indicating poor returns on capital.
- Analyst Downgrades & Uncertainty: Analyst sentiment is mixed with recent downgrades to 'Hold' from firms like Argus and Jefferies in early 2026. Revenue estimates for the next period show a wide range from $3.22B to $3.96B, signaling high uncertainty and limited coverage (only 5 analysts).
- Potential Technical Overextension: Trading at $20.69, the stock is just $0.13 below its 52-week high of $20.82. This leaves minimal upside buffer and increases vulnerability to a sharp pullback if momentum stalls, as evidenced by the -18.53% historical max drawdown.
DOC Technical Analysis
The stock is in a strong, sustained uptrend, evidenced by a 1-year price change of +18.23% and a year-to-date gain of +27.72%. As of the latest close at $20.69, the price is trading near the top of its 52-week range, approximately 99.4% of the distance from its 52-week low of $15.70 to its high of $20.82, indicating significant momentum but also potential overextension. Recent momentum has been exceptionally strong, with the stock surging +21.85% over the past 3 months and +5.83% over the past month, significantly outperforming the S&P 500 (SPY), which returned +12.0% and -0.08% over the same periods, respectively. This acceleration, particularly the sharp gap up in early May 2026, suggests a powerful bullish breakout that has diverged positively from the broader market's recent weakness. Key technical support is anchored at the 52-week low of $15.70, while immediate resistance is at the 52-week high of $20.82. A confirmed breakout above $20.82 would signal a continuation of the powerful uptrend and could target new highs. The stock exhibits market-average volatility with a beta of 1.029, meaning its price movements are generally in line with the broader market, which is notable given the recent explosive outperformance. The average daily volume of approximately 5.27 million shares provides sufficient liquidity for institutional participation in this move.
Beta
1.03
1.03x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$16-$21
Price range past year
Annual Return
+17.2%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | +3.8% | +1.5% |
| 3m | +15.5% | +13.4% |
| 6m | +22.4% | +10.9% |
| 1y | +17.2% | +24.5% |
| ytd | +24.0% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $719.4 million representing a year-over-year increase of 3.07%. However, examining the quarterly trend reveals inconsistency; revenue grew from $694.3 million in Q2 2025 to $705.9 million in Q3 and $719.4 million in Q4, but net income has been volatile, swinging from a loss of -$117.1 million in Q3 to a profit of $114.0 million in Q4. The company's primary revenue segment, Outpatient Medical Buildings, contributed $626.5 million, underscoring its importance to the overall business. Profitability is inconsistent on a quarterly basis, as seen with the Q4 2025 net income of $114.0 million contrasting with the Q3 2025 net loss of -$117.1 million. The trailing twelve-month net margin is a thin 2.53%, and the gross margin for Q4 2025 was deeply negative at -87.2%, though this appears to be a quarterly anomaly as other quarters show positive gross margins (e.g., 58.6% in Q3 2025). The operating margin for Q4 2025 was a healthier 20.27%, indicating core operations are profitable despite the unusual cost structure in that period. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.39. Financial health is supported by strong cash generation, with free cash flow over the trailing twelve months at $1.17 billion. The current ratio of 1.09 indicates adequate short-term liquidity. Return on equity is low at 0.95%, and return on assets is 1.50%, suggesting the company is not currently generating high returns on its capital base, which is a point for fundamental scrutiny.
Quarterly Revenue
$719402000.0B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
-0.87%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Given that Net Income for the most recent quarter (Q4 2025) is positive at $114.0 million, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is extremely high at 156.9x, while the forward PE is also elevated at 137.9x. The gap between trailing and forward multiples suggests the market expects earnings to improve, but both levels indicate the stock is priced for significant future growth or contains non-recurring items affecting earnings. Compared to sector averages, the stock trades at a substantial premium. Its Price-to-Sales ratio of 3.97 and EV-to-EBITDA of 13.16 are key metrics for REITs, but direct industry average comparisons are not provided in the data. The high PE multiples, especially relative to its modest growth and profitability metrics, suggest the market is assigning a premium valuation that may be difficult to justify on current fundamentals alone. Historically, the stock's own valuation has fluctuated widely. The current trailing PE of 156.9x is near the extreme high end of its recent historical range, which has seen figures from as low as 8.7x to over 779x in recent quarters. Trading near historical highs suggests the market is pricing in very optimistic expectations, leaving little room for disappointment and increasing downside risk if growth fails to materialize.
PE
156.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~780x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Healthpeak's primary financial risk is its inconsistent profitability, with net income swinging from a $114M profit in Q4 2025 to a $117M loss in Q3 2025. The trailing net margin of 2.53% and low ROE of 0.95% indicate inefficient capital deployment. While the company has strong FCF and a manageable debt-to-equity ratio of 1.39, its earnings volatility makes dividend coverage and valuation justification challenging. The stock's high valuation (PE of 156.9x) is critically dependent on future earnings growth materializing.
Market & Competitive Risks: The paramount market risk is valuation compression. Trading at a trailing PE of 156.9x, the stock is priced for perfection and is highly vulnerable to a de-rating if growth disappoints or interest rates rise, which negatively impacts REIT valuations. With a beta of 1.03, its price moves with the market, but its recent outperformance (+27.72% YTD vs. SPY's +8.77%) has created a performance gap that could close rapidly in a risk-off environment. Limited analyst coverage (5 firms) and recent downgrades suggest waning institutional conviction.
Worst-Case Scenario: The worst-case scenario involves a simultaneous failure of growth and a valuation re-rating. This could be triggered by a Q4 earnings miss, a guidance reduction, or a broader market sell-off that targets overvalued stocks. In this scenario, the stock could retrace its entire 2026 rally, falling back to its 52-week low of $15.70. From the current price of $20.69, this represents a potential loss of approximately -24%. A more severe de-rating, given the extreme PE, could see the stock fall below this level, testing support from the sharp gap-up that began in early May 2026 around $16.50.
FAQ
The primary risk is valuation compression (High Severity): the stock's 156.9x PE ratio leaves it vulnerable to a sharp decline if earnings growth fails to meet lofty expectations. The second risk is earnings volatility (Medium Severity): quarterly net income has swung from a $117M loss to a $114M profit, making future performance unpredictable. The third risk is momentum reversal (Medium Severity): the stock is trading at 99.4% of its 52-week high after a 21.85% 3-month surge; a technical breakdown could trigger rapid selling. Finally, limited analyst coverage (Low Severity) with only 5 firms can lead to higher volatility and less efficient price discovery.
The 12-month outlook for DOC presents three scenarios. The Base Case (55% probability) sees the stock consolidating between $18.50 and $20.50 as momentum fades and valuation normalizes, assuming modest ~3% revenue growth. The Bear Case (25% probability) projects a decline to $15.70-$17.50 if the valuation premium collapses due to an earnings miss or rising rates. The Bull Case (20% probability) envisions a rally to $22-$24 if the company delivers accelerating growth that justifies its multiple. The Base Case is most likely, centered on the stock's current technical strength being offset by its extreme valuation, leading to range-bound action.
DOC stock is significantly overvalued based on earnings. Its trailing PE ratio of 156.9x and forward PE of 137.9x are at the extreme high end of its historical range and are unsustainable for a company with low, volatile profitability (TTM net margin of 2.53%). While its Price-to-Sales (3.97x) and EV/EBITDA (13.16x) ratios are more reasonable for a REIT, the extreme earnings multiple implies the market is pricing in a dramatic and immediate acceleration in earnings growth that has not yet materialized. The valuation is disconnected from current fundamentals.
DOC is not a good buy at current levels for most investors. While the technical breakout is strong, the stock is extremely overvalued with a trailing PE of 156.9x against only 3.07% revenue growth, creating a poor risk/reward setup. The 27.72% YTD run-up has likely priced in near-term optimism, leaving significant downside risk if growth disappoints. It could be a speculative trading vehicle for momentum investors with tight stop-losses, but it is not suitable for prudent, long-term investment given the valuation disconnect.
DOC is suitable only for short-term, tactical investment based on momentum trading. Its high valuation (PE 156.9x), earnings volatility, and beta of 1.03 make it a poor candidate for a long-term, buy-and-hold portfolio. The recent explosive price move suggests it is being driven by technical factors and sentiment, not long-term fundamentals. Investors considering DOC should have a short-term horizon (weeks to months), use strict stop-loss orders, and be prepared to exit quickly if the $19 support level breaks. A minimum holding period is not advisable; it should be traded, not held.